Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities

NCT ID: NCT04667416

Last Updated: 2024-03-20

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-19
• Study Completion Date: 2025-01-31

Brief Summary

The purpose of this study is to assess the safety and preliminary efficacy of PalinGen® Flow for the treatment of chronic ulcers of the lower legs and feet.

Conditions

Chronic Ulcer of Lower Extremity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard of Care (SOC)

Participants will receive SOC for chronic ulcers of the lower extremities.

Group Type: NO_INTERVENTION

No interventions assigned to this group

PalinGen Flow Treatment plus SOC

Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.

Group Type: EXPERIMENTAL

PalinGen Flow Amniotic Tissue Allograft

Intervention Type: BIOLOGICAL

Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.

Interventions

PalinGen Flow Amniotic Tissue Allograft

Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Able to read, understand and sign the informed consent form (ICF)
• Available and willing to complete all study assessments
• At least 12 weeks post lower extremity revascularization procedure, if one has been performed
• Have chronic ulcer(s) of the lower extremities with the following characteristics:

• Of diabetic or vascular etiology
• Duration of ≥4 weeks, unresponsive to SOC
• ≤20 cm2 in area
• Extend through the full thickness of the skin but not down to muscle, tendon, or bone
• For subjects with VLU:

• Ulcer area is ≥1.5 cm2 and ≤20 cm2 and with a clean, granulating base with minimal adherent slough
• Ulcer location is at or above the ankle (malleolus) and below the knee
• Ulcer location is appropriate for use of compression therapy treatment
• For subjects with DFU:

• Ulcer area is ≥1.5 cm2 and ≤ 20 cm2 and is amenable to off-loading
• Subject has diabetes mellitus (Type 1 or Type 2), requiring insulin or oral/injectable medications to control blood glucose levels
• Glycosylated hemoglobin (HbA1c) level at screening is <12%
• Adequate circulation to the affected lower extremities
• Total serum bilirubin, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), hemoglobin, WBC, and PLT count all within limits specified in study protocol
• No renal impairment or mild renal impairment, defined as creatinine clearance ≥50 mL/min (by Cockroft-Gault estimation)
• Male subjects and female subjects of childbearing potential must use acceptable methods of contraception

Exclusion Criteria

• Clinical evidence of ongoing infection and/or receipt of IV, oral, or topical antimicrobials at the Baseline Visit
• Wheelchair bound or bed-ridden (ambulatory with assistance is acceptable)
• Ulceration at the site of amputation
• Undergoing renal dialysis
• Known or suspected malignancy in the target ulcer, or a history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancer)
• Documented history of osteomyelitis at the target ulcer location within 6 months of screening
• Current treatment or anticipated need for treatment over the course of the study with:

• Immunosuppressants (including topical or systemic corticosteroids or glucocorticoids)
• Cytotoxic chemotherapy
• Growth hormone
• Oral or systemic antifungal or antituberculosis treatment
• History of radiation at the ulcer site
• New York Heart Association Class III or IV congestive heart failure or uncontrolled cardiac dysrhythmia
• Diagnosis of autoimmune disease(s) (rheumatoid arthritis, lupus, psoriasis, Sjogren's syndrome) or arthritis requiring corticosteroid treatment
• Target ulcer(s) previously treated with negative pressure, hyperbaric oxygen, or tissue engineered materials (eg, Apligraf®, EpiFix® or Dermagraft®) or other scaffold materials (eg, Oasis, Matristem) within 4 weeks prior to Screening Visit
• Target ulcer(s) anticipated to require negative pressure wound therapy or hyperbaric oxygen at any time during the study
• Subjects with VLU who have:

• Deep vein thrombosis diagnosed within 4 weeks prior to Screening Visit
• Refusal or inability to tolerate compression therapy
• Subjects with DFU who have:

• Active Charcot foot (stable chronic Charcot foot is not exclusionary)
• Ulcers on toes 2, 3, 4, and/or 5 only (ulcer on plantar surface of the great toe only is not exclusionary)
• Pregnant or breast feeding
• Allergic to DMSO
• Healing of target ulcer is observed to be ≥35% at the end of the Run-in Period (between Screening and Baseline Visits)
• Presence of any condition(s) which compromises the subject's ability to complete this study, including subjects with a known history of poor adherence to medical treatment
• Subjects who, in the opinion of the Investigator, are not able to comply with study requirements
• Treatment with an investigational drug(s) or device(s) within the 4 weeks preceding Screening

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amnio Technology, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joseph M Caporusso, D.P.M.

Role: PRINCIPAL_INVESTIGATOR

Futuro Clinical Trials

Locations

Center for Clinical Research

Carmichael, California, United States

Center for Clinical Research

Castro Valley, California, United States

Limb Preservation Platform

Fresno, California, United States

Center for Clinical Research

San Francisco, California, United States

ILD Research Center

Vista, California, United States

Acclaim Bone & Joint Institute and Plastic Surgery

Fort Worth, Texas, United States

Futuro Clinical Trials

McAllen, Texas, United States

Countries

United States

Other Identifiers

PGF-201

Identifier Type: -

Identifier Source: org_study_id